Help influence Scotland’s assessment of drugs

What’s the project?

At Breast Cancer Now, with the help of our supporters, we work hard to ensure patients can access clinically effective breast cancer drugs on the NHS as quickly as possible.

We need your help to influence Scotland’s assessment of the following drugs treatments:

• Alpelisib (Piqray) in combination with fulvestrant for treating certain patients with hormone-receptor positive, PIK3CA-mutated locally advanced or secondary breast cancer.
• Abemaciclib (Verzenios) with hormone therapy for the treatment of hormone receptor positive, HER2‑negative, node‑positive primary breast cancer after surgery which is at higher risk of recurrence.

Both of these drug treatments have recently been approved for use on the NHS in England, and we now need to make sure the same happens in Scotland.

Please share this opportunity with your networks to ensure we can make more voices heard in this important decision.

Why do you want me to be involved?

Breast Cancer Now is involved at every step of the drug assessment process to ensure the voices of people affected by breast cancer are heard. Sharing your views helps decision makers understand what patients think about drug treatments. It doesn’t take long to share your views, but it can have a huge impact on the process.

What will you ask me to do?

We would love to hear your thoughts on either of the two drug treatments. You can do this by answering a couple of short questions about your views on the treatment via email or we can arrange a short call at a time that suits you. Any views will be included in our submission anonymously.

Who can take part?

We’re looking to hear views from patients from across the UK with experience of either of the two drug treatments.